Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.57 |
| ▸ | KDR | P35968 | 7/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636665 | 1.00 | EGFR (0.57) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30636666 | 0.81 | PDE4A (0.47) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29532044 | 0.81 | SMN1; SMN2 (0.56) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2330774 | 0.81 | PDE4A (0.47) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL294809 | 0.81 | SMN1; SMN2 (0.56) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL372023 | 0.80 | PDE4A (0.62) | EGFRKDRSMN1; SMN2KDM4EPDE4A | |
| SCHEMBL3318468 | 0.80 | SMN1; SMN2 (0.55) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11320298 | 0.80 | SMN1; SMN2 (0.55) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29642054 | 0.79 | POLB (0.59) | EGFRKDRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL611438 | 0.79 | POLB (0.59) | EGFRKDRHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108276393-B | Synthesis method of doxazosin impurity | 合肥华方医药科技有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-116854674-A | Preparation method of terazosin hydrochloride and intermediate thereof | 迪嘉药业集团股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-108276393-B | Synthesis method of doxazosin impurity | 合肥华方医药科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-108276393-B | Synthesis method of doxazosin impurity | 合肥华方医药科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-108276395-B | Preparation method of doxazosin impurity | 合肥华方医药科技有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-108276393-A | A kind of synthetic method of Doxazosin impurity | 合肥华方医药科技有限公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-108276395-A | A kind of preparation method of Doxazosin impurity | 合肥华方医药科技有限公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-102216283-B | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2013-11-27 | — | — | CN | disclosed |
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| CN-102216283-A | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN LA ROCHE | 2011-10-12 | — | — | CN | disclosed |
| EP-2346848-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
| WO-2010054968-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | EGFR 2117/4885KDR 867/4885HTT 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.